Pharma Mar
€71.40Change from previous close: +0.92%Absolute change: +€0.65
At a glance
- Revenue growth
- +26.61%
- 2025 vs 2024
- Net income growth
- +187.03%
- 2025 vs 2024
- Net margin
- 33.9%
- 2024: 14.9%
Financial data
Amounts in millions of EUR; per-share values in EUR; shares in millions.
| Item | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 3.4 | 8.6 | 33.6 | 16.7 | 9.1 | -6.3 | 1.7 | 4.2 | -9.2 | 9.3 | -2.7 | -7.0 |
| Depreciation and amortization | 2.1 | 2.1 | 1.7 | 2.0 | 2.0 | 2.0 | 1.1 | 1.5 | 1.6 | 1.5 | 0.5 | 1.5 |
| Capital expenditure | -2.3 | -1.3 | -3.3 | -1.2 | -1.4 | -0.5 | -1.4 | -3.7 | -2.6 | -7.3 | -4.6 | -4.5 |
| Investing cash flow | -32.4 | 29.0 | -58.2 | 12.9 | -26.8 | 11.3 | 20.4 | 0.9 | 6.7 | -27.0 | 1.7 | 6.2 |
| Financing cash flow | -0.1 | -7.0 | -7.6 | -2.0 | -20.0 | -6.8 | 4.2 | 10.8 | -13.6 | -6.7 | -6.3 | -6.4 |
| Dividends paid | — | — | 0.0 | — | -13.9 | — | — | — | -11.4 | — | — | — |
| Share repurchases | -2.3 | — | -21.7 | -2.0 | -5.5 | -7.7 | -8.5 | -3.2 | -1.9 | -5.1 | -6.0 | -8.0 |
| Debt issued | — | — | 1.3 | -2.3 | -2.1 | 2.1 | — | 15.0 | 0.4 | — | 2.3 | 0.4 |
| Debt repaid | -2.1 | -2.7 | -3.1 | 0.2 | 1.5 | -1.9 | -3.5 | -1.0 | -1.4 | -3.6 | -2.6 | -1.1 |
| Effect of exchange rates | -0.4 | 0.5 | 0.3 | 0.6 | -1.0 | -1.2 | 2.1 | -0.5 | -0.3 | 0.1 | -1.2 | -0.3 |
| Net change in cash | -29.5 | 31.0 | -31.9 | 28.1 | -38.7 | -2.9 | 28.4 | 15.5 | -16.4 | -24.3 | -10.0 | -6.1 |
| Free cash flow | 1.1 | 7.2 | 30.2 | 15.5 | 7.7 | -6.8 | 0.3 | 0.5 | -11.8 | 2.0 | -7.2 | -11.5 |
| Levered free cash flow | 2.4 | 6.7 | 7.4 | 24.3 | -3.5 | -5.4 | -5.9 | -2.0 | -11.7 | -1.6 | -3.0 | -5.8 |